Tuesday, Jul 17 2018 | Time 03:48 Hrs(IST)
image
image
  • Trump, after Helsinki summit, says he has confidence in U S intelligence
  • Russia might seek peacemaker role after World Cup, Helsinki summit -Finland
  • U S launches five WTO challenges to retaliatory tariffs
  • U S launches five WTO challenges to retaliatory tariffs
Science Technology Share

Dengvaxia, a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur

Dengvaxia,  a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur

Kolkata, Dec 5 (UNI) There continues to be a strong public health need for effective preventive interventions against dengue, a disease caused by four viruses, termed serotypes 1-4.

One dengue vaccine has been licensed, Dengvaxia (also referred to as CYD-TDV), developed by Sanofi Pasteur. Dengvaxia is a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur, given as a 3-dose series on a 0/6/12 month schedule.

Dengvaxia is the first dengue vaccine to be licensed and has now been approved by 19 regulatory authorities for use in endemic areas in persons typically ranging from 9-45 (in some countries 9-60) years of age.

It has been introduced in two subnational programs in the Philippines and Brazil targeting about one million individuals. It is otherwise available on the private market in countries where there is a marketing authorization.

Dengvaxia has been evaluated in two Phase 3 clinical trials (CYD14 trial in five countries in Asia and CYD15 trial in five countries in Latin America). Together, these trials included over 30,000 participants aged 2 to 16 years.

Vaccine efficacy against confirmed dengue pooled across both trials was 59.2 per cent in the year following the primary series, and 79.1 per cent against severe dengue. Efficacy varied by serotype, by age at vaccination and serostatus at baseline (i.e., previous exposure to dengue prior to vaccination).

While efficacy was reported against hospitalized and severe dengue in Years 1 and 2 post-dose 1, an excess of cases of hospitalized and severe dengue cases in those receiving Dengvaxia was seen in Year 3 in some subgroups, although it is based on relatively small numbers of cases. Whether the increased risk was due to age or serostatus at baseline, which is highly correlated with age, could not be fully clarified with the available data at the time.

For subjects aged 9 and above, in the first 25 months of the phase 3 trials, there was a reduction in severe dengue by 93 per cent and a reduction in hospitalizations by 81 per

cent.

MORE UNI BM SJC

More News
Aadhaar in Ayushman Bharat 'not must', clarifies Govt

Aadhaar in Ayushman Bharat 'not must', clarifies Govt

12 Jul 2018 | 3:50 PM

New Delhi, July 12 (UNI) Dismissing media reports that Aadhaar Card would be “must” to avail benefits under the Ayushman Bharat, the Centre on Thursday clarified that Aadhaar was 'desirable' and 'not must'.

 Sharesee more..
Leeches blood-clotting ability can help develop cures: Study

Leeches blood-clotting ability can help develop cures: Study

12 Jul 2018 | 11:29 AM

New Delhi, July 12 (UNI) Blood-feeding leeches have a suite of anticoagulant compounds they secrete from their salivary glands that prevent clotting.

 Sharesee more..

Global platform passes major milstone with publication of one-billionth species record

10 Jul 2018 | 10:08 AM

Hyderabad, Jul 10 (UNI) A global platform for sharing information about the world’s biodiversity has passed a major milestone, with the publication of the one-billionth species record of where a species lives through the Global Biodiversity Information Facility (GBIF).

 Sharesee more..
Quantum science-based university coming up in Jaipur

Quantum science-based university coming up in Jaipur

08 Jul 2018 | 1:29 PM

Jaipur, July 8 (UNI) The Centre for Quantum Activism, World Headquarters, Jaipur - a part of Prof Amit Goswami's world wide-campaign - is all set to open a quantum technology-based university for transformative education here.

 Sharesee more..

iZIM2018 begins; Scientists to use Zebrafish as a model system for Research

05 Jul 2018 | 6:24 PM

Hyderabad, Jul 5 (UNI) The four-day iZIM2018 (Indian Zebrafish Investigators Meeting) now underway at the CSIR-Centre for Cellular and Molecular Biology (CCMB), here, has brought together all the Indian scientists who use Zebrafish as a model system for research.

 Sharesee more..
image